Understanding why adults stop using continuous glucose monitoring after trying it
After ONBOARDing: Examining drivers of CGM discontinuation following a CGM uptake trial
This study is looking into why adults with type 1 diabetes stop using continuous glucose monitors (CGMs) after starting, so we can find ways to help them keep using this helpful technology and make managing their diabetes easier.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11002009 on NIH RePORTER |
What this research studies
This research investigates the reasons why adults with type 1 diabetes discontinue the use of continuous glucose monitoring (CGM) devices after initially adopting them. It aims to identify the barriers that lead to discontinuation and to develop targeted interventions to encourage sustained use of CGM technology. By analyzing data from participants who have tried CGM, the study seeks to refine a behavioral intervention called ONBOARD, which addresses common challenges faced by users. The ultimate goal is to improve glycemic control and reduce the burden of diabetes management for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have type 1 diabetes and have previously tried using a CGM device.
Not a fit: Patients who have never used a continuous glucose monitoring device or those with type 2 diabetes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved long-term health outcomes for adults with type 1 diabetes by promoting consistent use of CGM devices.
How similar studies have performed: Previous research has shown that behavioral interventions can effectively improve technology adoption and adherence in diabetes management, suggesting potential for success in this study.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Tanenbaum, Molly Leah — Stanford University
- Study coordinator: Tanenbaum, Molly Leah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.